Value through Innovation18 April 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive


New efficacy and safety data adds to evidence supporting treatment with afatinib*(GIOTRIF®) in Asian and non-Asian lung cancer patients

- For NON-US media only

New once-daily Striverdi* (olodaterol) Respimat® gains approval in first EU countries

- For media outside the UK, U.S. and Canada

Boehringer Ingelheim submits nintedanib*, a novel oncology compound, for European approval

- For non U.S. Media Only

Investigational interferon-free regimen demonstrates undetectable hepatitis C virus in all patients reaching end of treatment in ongoing Phase II trial

- For media outside of the U.S.A., UK and Canada only

Better outcome in case of major bleed for patients taking the anticoagulant Pradaxa® compared to warfarin

- For media outside of the US, the UK & Canada only

Ben Venue Laboratories, Inc. to Cease Production


Nintedanib* extended survival beyond one year for advanced adenocarcinoma patients after prior first-line chemotherapy

- For non U.S. Media Only

Boehringer Ingelheim Animal Health achieves milestone: 500 million pigs benefit from Mycoplasma vaccination


Boehringer Ingelheim significantly expands its production footprint in China


GIOTRIF® (afatinib)* approved in Europe for patients with EGFR mutation positive lung cancer

- For non U.S. Media Only

Data presented at EASD support safety profile of Trajenta® (linagliptin) in broad range of adults with Type 2 Diabetes

- For Non-US and Non-UK Media

Pooled analysis data showed improvements in glycaemic parameters, body weight and blood pressure with investigational agent empagliflozin* in adults with Type 2 Diabetes

- For Non-US and Non-UK Media

New poll highlights treatment priorities of European primary care physicians when managing Type 2 Diabetes

- Ex -US & Ex- UK Medical Media Only

Ventana to collaborate with Boehringer Ingelheim on the development of companion diagnostic tests


Boehringer Ingelheim and Eli Lilly and Company present efficacy and safety data on linagliptin and investigational compound, empagliflozin* in various diabetes subpopulations

- Ex -US & Ex- UK Medical Media Only

Volasertib* receives FDA Breakthrough Therapy designation for treatment of patients with acute myeloid leukaemia

- For non-U.S. media only

Boehringer Ingelheim broadens efforts for interferon-free hepatitis C treatments through clinical collaboration with Presidio Pharmaceuticals

- For media outside USA, UK and Canada only

ERS Congress 2013
Phase III results: Once daily olodaterol* Respimat® provides effective and sustained improvements in lung function in patients with COPD1-3

- For media outside the UK, U.S. and Canada